Share on StockTwits

Intrexon Corp (NYSE:XON)‘s stock had its “equal weight” rating reaffirmed by equities research analysts at Barclays in a research note issued to investors on Thursday, AnalystRatings.Net reports. They currently have a $18.00 price target on the stock, down from their previous price target of $25.00. Barclays’ price objective points to a potential upside of 16.96% from the company’s current price.

Shares of Intrexon Corp (NYSE:XON) traded down 1.43% during mid-day trading on Thursday, hitting $15.17. The stock had a trading volume of 1,253,570 shares. Intrexon Corp has a 52 week low of $15.06 and a 52 week high of $38.50. The stock has a 50-day moving average of $22.29 and a 200-day moving average of $24.31. The company’s market cap is $1.484 billion.

Intrexon Corp (NYSE:XON) last released its earnings data on Wednesday, May 7th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.02. The company had revenue of $7.90 million for the quarter, compared to the consensus estimate of $11.25 million. During the same quarter in the previous year, the company posted ($7.54) earnings per share. The company’s revenue for the quarter was up 102.6% on a year-over-year basis. Analysts expect that Intrexon Corp will post $-0.23 EPS for the current fiscal year.

Intrexon Corporation is engaged in the business of synthetic biology. Using the Company’s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (NYSE:XON) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.